Pediatrix Medical Group, Inc.
MDNYSECIK 893949HealthcareFiscal year ends Dec 31
Reports and events: 259 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2907:00 ET | 10-Q | Quarterly reportPeriod 2026-09-30 | 0001193125-26-436952 |
| 2026-10-2906:50 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-436932 |
| 2026-08-0407:00 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-331513 |
| 2026-08-0406:50 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-331488 |
| 2026-07-2417:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure | 0001193125-26-316225 |
| 2026-07-1507:00 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-304033 |
| 2026-05-0716:30 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-212117 |
| 2026-05-0507:00 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-204993 |
| 2026-05-0506:50 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-204982 |
| 2026-03-2706:50 ET | DEF 14A | Proxy statementPeriod 2026-03-25 | 0001193125-26-127299 |
| 2026-02-1907:00 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-058074 |
| 2026-02-1906:50 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-058063 |
| 2025-11-0307:00 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-261640 |
| 2025-11-0306:50 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-261626 |
| 2025-08-1816:45 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-109777 |
| 2025-08-0507:00 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-102382 |
| 2025-08-0506:50 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-102375 |
| 2025-07-0116:30 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-092261 |
| 2025-05-0816:30 ET | 8-K | 5.07 Shareholder vote results | 0000950170-25-067076 |
| 2025-05-0607:00 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-063951 |
| 2025-05-0606:50 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-063946 |
| 2025-04-1816:30 ET | 8-K | 1.01 Entry into a material agreement | 0000950170-25-055880 |
| 2025-03-2806:52 ET | DEF 14A | Proxy statementPeriod 2025-03-26 | 0000950170-25-046327 |
| 2025-02-2007:00 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-023730 |
| 2025-02-2006:50 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-023723 |
| 2025-01-1416:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-006190 |
| 2025-01-1306:50 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-004937 |
| 2024-12-0516:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-24-133723 |
| 2024-11-0107:00 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-119796 |
| 2024-11-0106:50 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-119795 |
| 2024-08-0607:00 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-091193 |
| 2024-08-0606:50 ET | 8-K | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-24-091185 |
| 2024-06-1716:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-24-074283 |
| 2024-05-3006:50 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-066242 |
| 2024-05-0916:30 ET | 8-K | 5.07 Shareholder vote results | 0000950170-24-057093 |
| 2024-05-0707:03 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-053922 |
| 2024-05-0706:50 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-053917 |
| 2024-04-2516:31 ET | 8-K | 1.01 Entry into a material agreement | 0000950170-24-048387 |
| 2024-03-2806:50 ET | DEF 14A | Proxy statementPeriod 2024-05-09 | 0001193125-24-079571 |
| 2024-02-2007:00 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-016794 |
| 2024-02-2006:50 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-016790 |
| 2023-11-0207:00 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-057738 |
| 2023-11-0206:50 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-057732 |
| 2023-08-0307:01 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-037565 |
| 2023-08-0306:50 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-037559 |
| 2023-05-1116:35 ET | 8-K | 5.07 Shareholder vote results | 0000950170-23-021326 |
| 2023-05-0416:16 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-23-017882 |
| 2023-05-0207:01 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0000950170-23-016430 |
| 2023-05-0206:50 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-016427 |
| 2023-03-3107:06 ET | DEF 14A | Proxy statement | 0001193125-23-086703 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 29, 2026, 07:14 ET. Listed shows no prices and gives no investment advice.